We appreciate the opportunity to respond to the comment [1] submitted by CADTH in regard to our commentary entitled “Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain” [2] published on 16 December 2022. Here, ERBB2 is linked to breast carcinoma.